engleski

Neuroendocrine tumor in large bowel biopsy

Large intestinal carcinoid tumors account for approximately 6% of all neuroendocrine tumors (NETs), with an equal sex distribution and incidence of 0.07-0.11 to up to 0.21 cases per 100, 000 population per year. It is reported at any age from 9 to 83 years, at 64 to 66 years of age on an average. We analyzed gastrointestinal endoscopic biopsies for carcinoid with respect to histopathologic particularities. In this retrospective cross-sectional study, 6500 gastrointestinal endoscopies routinely performed at Department of Gastroenterology from January 1, 2008 till March 31, 2009 were analyzed. The diagnosis was established according to a set of typical histological findings with standard hematoxylin and eosin staining and immunohistochemistry (synaptophysin, chromogranin). Of all gastrointestinal biopsies analyzed, there were 5 (0.08%) cases of neuroendocrine tumor. Three of these 5 cases were found in the stomach, and one in the duodenum and colon each. In addition, five carcinoids from our database were diagnosed after wide intestinal resection, where one specimen was from the small intestine, two specimens were from the ascending colon, one from the appendix, and one was located in the rectosigmoid. Colonic neuroendocrine tumor is associated with worst prognosis among all gastrointestinal carcinoid tumors, with an overall 5-year survival of 33% to 42%. The features such as tumor size and microinvasion tend to be less useful on assessing the prognosis of colonic carcinoid than in other gastrointestinal locations, because at the time of presentation the tumor exceeds 2 cm in size and involves the muscularis propria. Large bowel endoscopic biopsy is a helpful tool in diagnosing NETs, thus regular clinical examinations in the population at risk may improve the overall survival rate.

Neuroendocrine tumor; large bowel biopsy

nije evidentirano